Evidence mapPaperPMID 41828542Full record

ReviewInternational journal of molecular sciences2026

The Ubiquitin-Specific Protease Family: Master Regulators of Renal Fibrosis Pathogenesis and Therapeutic Targets.

Yinhang Wang, Dadui Ren, Wenjun Zhao, Yongmei Zhang, Xuemei Zhang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yinhang WangJoint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University, & School of Pharmacy, East China Normal University, Shanghai 200241, China.ORCID 0009-0008-4427-0164
Dadui RenInstitute of Biomedical Research, Henan Academy of Sciences, Zhengzhou 450046, China.
Wenjun ZhaoDepartment of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing 100053, China.
Yongmei ZhangInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.
Xuemei ZhangJoint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University, & School of Pharmacy, East China Normal University, Shanghai 200241, China.

Funding

Minhang District Science and Technology Commission Foundation 2022MHZ013National Natural Science Foundation of China 82304598Shanghai Sailing Program 22YF1439800
6 · The paper itself

Abstract

Ubiquitin-specific proteases (USPs) constitute the largest and most diverse family of deubiquitinating enzymes (DUBs), playing a pivotal role in maintaining protein homeostasis through reversible post-translational modifications (PTMs). Renal fibrosis represents the final common pathway of various chronic kidney diseases (CKDs), ultimately leading to irreversible nephron loss and end-stage renal disease (ESRD). With CKD affecting over 10% of the global adult population, fibrosis imposes a substantial clinical and economic burden. Despite this, effective antifibrotic therapies remain clinically elusive. Emerging evidence highlights the critical involvement of USPs in the pathogenesis of renal fibrosis through the potentiation of pro-fibrotic signaling pathways, inflammation, oxidative stress, cell cycle arrest and cellular senescence, as well as some other pathways. This review comprehensively summarizes the current understanding of USPs in renal fibrosis, detailing their structural characteristics, molecular mechanisms, and specific regulatory roles. Furthermore, we discuss recent advances in developing small-molecule USP inhibitors, providing novel insights into targeting the ubiquitin-proteasome system as a promising therapeutic strategy for combating renal fibrosis.

Indexed as

Kidney DiseasesUbiquitin-Specific ProteasesAnimalsFibrosisHumansProtein Processing, Post-TranslationalSignal TransductionUbiquitin-Specific Proteasesdeubiquitinationrenal fibrosisubiquitin-specific protease

Identifiers

PMID41828542
PMCPMC12985270

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.